Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTERNATIONAL BUSINESS MACHINES CORPORATION

(IBM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

International Business Machines : IBM and The Michael J. Fox Foundation use AI to help predict progression of Parkinson's disease

07/30/2021 | 03:19am EDT

Chances are, you know that Michael J. Fox-the actor who played Marty McFly in the iconic 'Back to the Future' movies-has Parkinson's disease. But when he first disclosed his condition in 1998, the world gasped. He revealed that he had been diagnosed seven years earlier, at the age of 29. Just a few years later, in 2000, Fox launched The Michael J. Fox Foundation for Parkinson's Research (MJFF) to help search for treatments and a cure for this condition that affects an estimated more than six million people, globally.

Since then, MJFF's team of in-house neuroscientists and business strategists have been working side-by-side with science and technology researchers, clinicians, industry partners and patients around the world to fund the most promising research to better understand and treat the disease. In July 2018, a unique partnership was launched between the Foundation and IBM Research to apply machine learning to advance scientific breakthroughs.

Recently, our collaboration has reached a significant milestone. In our latest work, 'Discovery of Parkinson's disease states using machine learning and longitudinal data,'1 published by our team, alongside scientists with MJFF in Lancet Digital Health, we detail a new AI model that groups typical symptom patterns of Parkinson's disease. The model also predicts the progression of these symptoms in timing and severity, by learning from what's known as longitudinal patient data-descriptions of a patient's clinical status gathered over time.

Our aim is to use AI to help with patient management and clinical trial design. These goals are important because, despite Parkinson's prevalence, patients experience a unique variety of motor and non-motor symptoms.

Hopefully, by using machine learning to learn from large amounts of patient data, clinicians and researchers could have a new tool to better predict the notoriously varying progression of symptoms in individual Parkinson's patients. They can then better manage and treat the disease, as well as use the best candidates for more targeted and effective clinical trials.

Putting AI to work

The results are the next step following our previously published research. That work focused on developing methods for some of the unique challenges of healthcare applications, including enabling personalized predictions2 and accounting for medications' effects on symptom measurements. This time, we tested our AI methods with data from the Parkinson's Progression Markers Initiative (PPMI). The Michael J. Fox Foundation sponsors this international study and makes its de-identified dataset-one of the largest Parkinson's datasets in the world-accessible to researchers.

PPMI is recruiting new volunteers. Visit michaeljfox.org/ppmi to learn more.

Having access to a large dataset is crucial for success in machine learning models, which is why the troves of data in the PPMI were key to our model's viability. The dataset served as the input to the machine learning approach, enabling the discovery of complex symptom and progression patterns.

While many previous studies have focused on characterizing Parkinson's disease using only baseline information, our method relies on up to seven years of patient data. Also, our model makes limited a priori assumptions about the progression pathways, compared to previous studies.

New insights into the disease's progression

These modeling decisions have allowed us to gain more insights into disease states and progression pathways. The results suggest that a patient's state can vary in several factors, including the ability to perform activities of daily living; issues around slowness of movement, tremor and postural instability; and non-motor symptoms such as depression, anxiety, cognitive impairment and sleep disorders.

We have found that the results support the hypothesis of diverse progression pathways, as indicated by the many disease trajectories we've observed. However, the AI model is still able to make accurate predictions. Having learned the model using one dataset, it was able to successfully predict an advanced state of Parkinson's disease associated with outcomes such as dementia and the inability to walk unassisted.

Because of the diversity of experiences in Parkinson's disease, we hope that by enabling such predictions, the model can help in patient management and provide more specific inclusion criteria and outcome definitions during clinical trial design.

There is still a lot of work to do, though. For example, we hope to refine the model to provide even more granular characterization of disease states by incorporating emerging biomarker assessments including genomic and neuroimaging measurements.

We are humbled to be a part of Michael J. Fox's vision for Parkinson's research and hope that together we will make a meaningful impact on the lives of patients around the world.

Disclaimer

IBM - International Business Machines Corporation published this content on 29 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 07:18:04 UTC.


© Publicnow 2021
All news about INTERNATIONAL BUSINESS MACHINES CORPORATION
09/15X-FORCE REPORT : No Shortage of Resources Aimed at Hacking Cloud Environments
PU
09/15INTERNATIONAL BUSINESS MACHINES : CaixaBank boosts digital capabilities with IBM..
PR
09/15CaixaBank Boosts Digital Capabilities with IBM Cloud for Financial Services, ..
CI
09/14ATOS : IBM To Create Center Of Excellence For Cloud Services
MT
09/14DISH NETWORK : Taps IBM's AI-Powered Automation Software for New Cloud-Native 5G..
MT
09/14INTERNATIONAL BUSINESS MACHINES : Atos to create center of excellence to acceler..
PR
09/14DISH Selects IBM's AI-Powered Automation and Network Orchestration Software a..
CI
09/14Temenos and IBM Collaborate to Accelerate Hybrid Cloud Adoption in the Financ..
CI
09/13IBM Enters into a Contract with the First Government Client of the IBM Health..
CI
09/13INTERNATIONAL BUSINESS MACHINES : Sumo Logic and IBM Expand Collaboration to Acc..
PU
More news
Analyst Recommendations on INTERNATIONAL BUSINESS MACHINES CORPORATION
More recommendations
Financials (USD)
Sales 2021 75 218 M - -
Net income 2021 6 926 M - -
Net Debt 2021 46 531 M - -
P/E ratio 2021 17,5x
Yield 2021 4,65%
Capitalization 121 B 121 B -
EV / Sales 2021 2,23x
EV / Sales 2022 2,16x
Nbr of Employees 345 900
Free-Float 39,8%
Chart INTERNATIONAL BUSINESS MACHINES CORPORATION
Duration : Period :
International Business Machines Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTERNATIONAL BUSINESS MACHINES CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 135,23 $
Average target price 149,14 $
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Arvind Krishna Chairman & Chief Executive Officer
James J. Kavanaugh Chief Financial Officer & Senior VP-Operations
Juan Antonio Zufiria Senior VP-Global Technology Services
Kathryn W. Guarini Chief Information Officer
Michael L. Eskew Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INTERNATIONAL BUSINESS MACHINES CORPORATION8.38%121 209
ACCENTURE PLC28.40%212 689
TATA CONSULTANCY SERVICES LTD.33.71%192 171
SNOWFLAKE INC.14.71%97 131
INFOSYS LIMITED34.68%96 186
AUTOMATIC DATA PROCESSING, INC.12.60%84 053